Jasper Positive Updated Phase 1b/2a Data for Briquilimab in CSU

 

• Briquilimab demonstrated rapid disease control and high complete response rates in CSU patients, with 83% achieving complete response by week 3 in the BEACON study.
• The open-label extension study showed 58% of CSU patients achieved a complete response at 12 weeks, with 75% achieving well-controlled disease.

https://www.dermatologytimes.com/view/jasper-therapeutics-announces-positive-updated-phase-1b-2a-data-for-briquilimab-in-csu